ๆญฏ60-1.PDF

Similar documents
Lumbar spine

388 The Korean Journal of Hepatology : Vol. 6. No COMMENT 1. (dysplastic nodule) (adenomatous hyperplasia, AH), (macroregenerative nodule, MR



Kaes010.hwp

Original Articles Korean Circulation J 1999;29 2 : ๋ ˆํŠธ๋กœ๋ฐ”์ด๋Ÿฌ์Šค๋ฅผ์ด์šฉํ•œ๋ฐฐ์–‘๋œ์‹ฌ๊ทผ์„ธํฌ๋กœ์˜์œ ์ „์ž์ „๋‹ฌ ํ—ˆ์ •์€ 1 ๊น€๋•๊ฒฝ 1 ๋ณ€์ข…ํšŒ 1 ๋ฐ•์„ ์ง„ 1 ์ „์€์„ 2 ์ตœ์œคํ˜ 1 ์ •์€์•„ 1 ๊ถŒํ˜„์ฒ  1 ๋ฐ•์Šน์šฐ 1 ๊น€์ค€์ˆ˜ 1 ์ด์ƒํ›ˆ 1


03์ด๊ฒฝ๋ฏธ(237~248)ok

433๋Œ€์ง€05๋ฐ•์ฐฝ์šฉ

untitled

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

ๆญฏ1.PDF

( )Kju269.hwp

Can032.hwp

7 1 ( 12 ) ( 1912 ) 4. 3) ( ) 1 3 1, ) ( ), ( ),. 5) ( ) ). ( ). 6). ( ). ( ).

ๆญฏ์ œ7๊ถŒ1ํ˜ธ(์ตœ์ข…ํŽธ์ง‘).PDF

01 Buffers & Gel Stain Buffers 3 Gel Stain SilverStar Staining Kit 6

<C7D1B1B9B1A4B0EDC8ABBAB8C7D0BAB85F31302D31C8A35F32C2F75F E687770>

๊ธฐ๊ด€๊ณ ์œ ์—ฐ๊ตฌ์‚ฌ์—…๊ฒฐ๊ณผ๋ณด๊ณ 


ํ™ฉ์ง€์›…

hwp

975_983 ํŠน์ง‘-ํ•œ๊ทœ์ฒ , ์ •์›ํ˜ธ

21์„ธ๊ธฐ ๋ฐ”์ด์˜ค ํ˜๋ช…

๋‹ฌ์ƒ์‚ฐ์ด ์ดˆ์‚ฐ๋ชจ ๋ถ„๋งŒ์‹œ๊ฐ„์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ โ… . ์„œ ๋ก  โ…ก. ์—ฐ๊ตฌ๋Œ€์ƒ ๋ฐ ๋ฐฉ๋ฒ• ้” ์€ 23) ์˜ ไธน ๆบช ์— ์ตœ์ดˆ๋กœ ๊ธฐ ์žฌ๋œ ์ฒ˜๋ฐฉ์œผ๋กœ, ์— ๋ณต์šฉํ•˜๋ฉด ํ•œ ๋‹คํ•˜์—ฌ ๋‚œ์‚ฐ์˜ ์˜ˆ๋ฐฉ๊ณผ ๋ฐ, ๋“ฑ์— ๋„๋ฆฌ ํ™œ์šฉ๋˜์–ด ์™”๋‹ค. ้” ์€ ์ด ๆฏ’ ํ•˜๊ณ  ๋Š” ็”˜ ่‹ฆ ํ•˜์—ฌ ๆฐฃ, ๆฐฃ ๅฏฌ,, ็ต ์˜ ํšจ๋Šฅ์ด ์žˆ


< D B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A E687770>

ํ•œ๊ตญ์„ฑ์ธ์—์„œ์ดˆ๊ธฐํ™ฉ๋ฐ˜๋ณ€์„ฑ์งˆํ™˜๊ณผ ์—ฐ๊ด€๋œ์œ„ํ—˜์š”์ธ์—ฐ๊ตฌ

A 617

Crt114( ).hwp

012์ž„์ˆ˜์ง„

Analysis of objective and error source of ski technical championship Jin Su Seok 1, Seoung ki Kang 1 *, Jae Hyung Lee 1, & Won Il Son 2 1 yong in Univ

<C7D1B1B9B1B3C0B0B0B3B9DFBFF85FC7D1B1B9B1B3C0B05F3430B1C733C8A35FC5EBC7D5BABB28C3D6C1BE292DC7A5C1F6C6F7C7D42E687770>

๋‰ด์Šค์ง€14ํ˜ธ-์นผ๋ผ


1..

. 45 1,258 ( 601, 657; 1,111, 147). Cronbach ฮฑ=.67.95, 95.1%, Kappa.95.,,,,,,.,...,.,,,,.,,,,,.. :,, ( )

( )Jkstro011.hwp

ยบรŽรยคยธร†รƒร–รยพ

ฮณ

7 1 ( 12 ) 1998 ( ) ( ) ( ) ( ) ( ). ( ) ( ). ( ) ( ) ( ). ( ). ( ) ( ) ( ) 3).., 16 ( ) ( ) ( ) ( ) ( ) ( ) ( ). 4). ( ) ( ) ( ),., 4-5, 6-7, 5) 6) (

09๊ตฌ์ž์šฉ(489~500)

:,,.,. 456, 253 ( 89, 164 ), 203 ( 44, 159 ). Cronbach ฮฑ= ,.,,..,,,.,. :,, ( )

์Šคํฌ์ธ ๊ณผํ•™ 143ํ˜ธ ๋‚ด์ง€.indd

<35BFCFBCBA2E687770>

16(1)-3(๊ตญ๋ฌธ)(p.40-45).fm

ํ•ญ์ฒด ํฌํ„ธ ์„œ๋น„์Šค Preparation Peptide ์ด 4์ฃผ ์†Œ์š” / 473,000 ~ 511,000 Free of charge 2~3 days 243,000 ~ 281,000 ์˜๋ขฐ์„œ ์ž‘์„ฑ Peptide epitope prediction ์œ ์ „์ž ์ •๋ณด

(Establishment and Management of Proteomics Core Facility)

Journal of Educational Innovation Research 2019, Vol. 29, No. 2, pp DOI: 3 * Effects of 9th

9(3)-4(p ).fm

44-4๋Œ€์ง€.07์ด์˜ํฌ532~


09รˆยซยผยฎยฟยต 5~152s

( )Kjhps043.hwp

์„์‚ฌ๋…ผ๋ฌธ.PDF

139~144 ยฟร€ยฐรธยพร ร„ยง

<313120B9DABFB5B1B82E687770>

<30382EC0C7C7D0B0ADC1C22E687770>

๊น€๋„ํฌ_HT protein expression ํ‘œ์ค€ ๋ณด๊ณ ์„œ_v1.5

์ถฉ๋ถ์˜๋Œ€ํ•™์ˆ ์ง€ Chungbuk Med. J. Vol. 27. No. 1. 1~ Charcot-Marie-Tooth Disease ํ™˜์ž์˜๋งˆ์ทจ : ์ฆ๋ก€๋ณด๊ณ  ์‹ ์ผ๋™ 1, ์ด์ง„ํฌ 1, ๋ฐ•์ƒํฌ 1,2 * ์ฑ…์ž„์ €์ž : ๋ฐ•์ƒํฌ, ์ถฉ๋ถ์ฒญ์ฃผ์‹œ์„œ์›๊ตฌ์ถฉ๋Œ€๋กœ 1 ๋ฒˆ์ง€, ์ถฉ๋ถ๋Œ€ํ•™๊ต

Treatment and Role of Hormaonal Replaement Therapy


A

03-์„œ์—ฐ์˜ฅ.hwp

Chapter 26

A 001~A 036

Abstract Background : Most hospitalized children will experience physical pain as well as psychological distress. Painful procedure can increase anxie

09-๊ฐ๋งˆ์„ (dh)

Kbcs002.hwp

ยบรŽรยคยธร†V10Nยณยปรรถ

์ œ 9 ๋„๋Š” 6์ œ์–ดํ•ญ๋ชฉ์˜ ์„ธํŒ…๋ชฉํ‘œ์˜ ๋ณด๊ธฐ๊ฐ€ ํ‘œ์‹œ๋œ ๋ ˆ์ด๋” ์ฑ ํŠธ(radar chart). ์ œ 10 ๋„๋Š” ์ œ 6 ๋„์˜ ํ•จ์ˆ˜๋ธ”๋Ÿญ(1C)์—์„œ ์‚ฌ์šฉ๋˜๋Š” ๊ฐ์ข… ๊ฐœ์„ฑํ™” ํ•จ์ˆ˜์˜ ๋ณด๊ธฐ๋ฅผ ํ‘œ์‹œํ•˜๋Š” ํ…Œ์ด๋ธ”. ์ œ 11a ๋„ ์ œ 11c ๋„๊นŒ์ง€๋Š” ๊ฐ์ข… ์กฐ๊ฑด์— ๋”ฐ๋ผ ์ œ๊ณต๋˜๋Š” ๊ฐœ์„ฑํ™”ํ•จ์ˆ˜์˜ ๋ณ€ํ™”์˜


ๆญฏFFF01379.PDF

Analyses the Contents of Points per a Game and the Difference among Weight Categories after the Revision of Greco-Roman Style Wrestling Rules Han-bong

<30352EB0A3BAB4B8AE2E687770>

00์•ฝ์ œ๋ถ€๋ด„ํ˜ธc03้€žํ’š

(Exposure) Exposure (Exposure Assesment) EMF Unknown to mechanism Health Effect (Effect) Unknown to mechanism Behavior pattern (Micro- Environment) Re

Microsoft Word - pv_0602.doc

#รˆยฒยฟรซยผยฎ

DBPIA-NURIMEDIA

(72) ๋ฐœ๋ช…์ž ์ด์Šน์› ๊ฐ•์›๋„ ๊ณ ์„ฑ๊ตฐ ์ฃฝ์™•๋ฉด ์˜คํ˜ธ๋ฆฌ ์ •๋™ํ˜ธ ๊ฐ•์›๋„ ๊ณ ์„ฑ๊ตฐ ์ฃฝ์™•๋ฉด ์˜คํ˜ธ๋ฆฌ ์ดํ˜ธ์ƒ ๊ฐ•์›๋„ ๊ณ ์„ฑ๊ตฐ ์ฃฝ์™•๋ฉด ์˜คํ˜ธ๋ฆฌ ์ด ๋ฐœ๋ช…์„ ์ง€์›ํ•œ ๊ตญ๊ฐ€์—ฐ๊ตฌ๊ฐœ๋ฐœ์‚ฌ์—… ๊ณผ์ œ๊ณ ์œ ๋ฒˆํ˜ธ PMS235A ๋ถ€์ฒ˜๋ช… ๊ตญํ† ํ•ด์–‘๋ถ€ ์—ฐ๊ตฌ์‚ฌ์—…๋ช… ํ•ด์–‘์ž์›๊ฐœ๋ฐœ ์—ฐ๊ตฌ๊ณผ์ œ๋ช…

<35335FBCDBC7D1C1A42DB8E2B8AEBDBAC5CDC0C720C0FCB1E2C0FB20C6AFBCBA20BAD0BCAE2E687770>

์ €์ž‘์žํ‘œ์‹œ - ๋น„์˜๋ฆฌ - ๋ณ€๊ฒฝ๊ธˆ์ง€ 2.0 ๋Œ€ํ•œ๋ฏผ๊ตญ ์ด์šฉ์ž๋Š”์•„๋ž˜์˜์กฐ๊ฑด์„๋”ฐ๋ฅด๋Š”๊ฒฝ์šฐ์—ํ•œํ•˜์—ฌ์ž์œ ๋กญ๊ฒŒ ์ด์ €์ž‘๋ฌผ์„๋ณต์ œ, ๋ฐฐํฌ, ์ „์†ก, ์ „์‹œ, ๊ณต์—ฐ๋ฐ๋ฐฉ์†กํ• ์ˆ˜์žˆ์Šต๋‹ˆ๋‹ค. ๋‹ค์Œ๊ณผ๊ฐ™์€์กฐ๊ฑด์„๋”ฐ๋ผ์•ผํ•ฉ๋‹ˆ๋‹ค : ์ €์ž‘์žํ‘œ์‹œ. ๊ท€ํ•˜๋Š”์›์ €์ž‘์ž๋ฅผํ‘œ์‹œํ•˜์—ฌ์•ผํ•ฉ๋‹ˆ๋‹ค. ๋น„์˜๋ฆฌ. ๊ท€ํ•˜๋Š”์ด์ €์ž‘๋ฌผ์„์˜๋ฆฌ๋ชฉ์ ์œผ๋กœ์ด์šฉํ• 

Trd022.hwp

Microsoft PowerPoint - ch03ysk2012.ppt [ํ˜ธํ™˜ ๋ชจ๋“œ]

untitled

DBPIA-NURIMEDIA

077~088 ํ•ด๊ณ„ ์œ ์นจ๊ณผ ์ „์นจ์ด

304.fm

605.fm

untitled

Journal of Educational Innovation Research 2018, Vol. 28, No. 4, pp DOI: 3 * The Effect of H

(....).hwp

ํ•œ๊ตญ์ „์ง€ํ•™ํšŒ ์ถ˜๊ณ„ํ•™์ˆ ๋Œ€ํšŒ Contents ๊ธฐ์กฐ๊ฐ•์—ฐ LI GU 06 ์ดˆ๊ฐ•์—ฐ ๊น€๋™์šฑ 09 ์•ˆ์žฌํ‰ 10 ์ •์ฐฝํ›ˆ 11 ์ด๊ทœํƒœ 12 ๋ฌธ์ค€์˜ 13 ํ•œ๋ณ‘์ฐฌ 14 ์ตœ์›์ฐฝ 15 ๋ฐ•์ฒ ํ˜ธ 16 ์•ˆ๋™์ค€ 17 ์ตœ๋‚จ์ˆœ 18 ๊น€์ผํƒœ 19 ํฌ์Šคํ„ฐ ๊ฐ•์ค€์„ญ 23 ์œค์˜์ค€ 24 ๋„์ˆ˜์ • 25 ๊ฐ•์ค€ํฌ 26

09๊ถŒ์˜ค์„ค_ok.hwp

ๆญฏ5-2-13(์ „๋ฏธํฌ์™ธ).PDF

Journal of Educational Innovation Research 2017, Vol. 27, No. 3, pp DOI: : A basic research

1. KT ์˜ฌ๋ ˆ์Šคํ€˜์–ด ๋ฏธ๋””์–ดํŒŒ์‚ฌ๋“œ ์ฝ˜ํ…์ธ  ๊ฐœ๋ฐœ.hwp

-, BSF BSF. - BSF BSF ( ),,. BSF -,,,. - BSF, BSF -, rrna, BSF.

Kor. J. Aesthet. Cosmetol., ๋ฐ ์ž์•„์กด์ค‘๊ฐ๊ณผ ์ŠคํŠธ๋ ˆ์Šค์™€๋„ ๋ฐ€์ ‘ํ•œ ๊ด€๊ณ„๊ฐ€ ์žˆ๊ณ , ๋งŒ์กฑ ์ •๋„ ์— ๋”ฐ๋ผ ์ „๋ฐ˜์ ์ธ ์ƒํ™œ์—๋„ ์˜ํ–ฅ์„ ๋ฏธ์น˜๋ฏ€๋กœ ์‹ ์ฒด๋Š” ๊ฐˆ์ˆ˜๋ก ๊ฐœ ์ธ์ , ์‚ฌํšŒ์  ์ฐจ์›์—์„œ ์ค‘์š”ํ•ด์ง€๊ณ  ์žˆ๋‹ค(์•ˆํฌ์ง„, 2010). ๋”ฐ๋ผ์„œ ์™ธ๋ชจ๋งŒ์กฑ๋„๋Š” ๊ฐœ์ธ์˜ ์‹ ์ฒด๋Š” ํƒ€

Transcription:

: 60 1 2001 plasmid VE GF, *,, * * * * * * * * * =A b s t r a c t = Ch ar ac t e ri s tic s of g e n e tra n s f e r an d V E GF e x p re s s i on u s in g n ak e d p la s m i d v e c t or s in th e rat h e art Jin - Ok Jeong, M.D. *, Sun - Jin P ark, B.S. *, Jeong - Eun Huh, M.S. *, Eun - Ah Jung, M.S.*, Ju Hyeon Oh, M.D. *, Hyeon - Cheol Gwon, M.D. *, YoungJoo Lee, Ph.D., Sunyoung Kim, Ph.D., Jeong - Euy Park, M.D. *, Won Ro Lee, M.D. *, Eun - Seok Jeon, M.D. and Duk - Kyung Kim, M.D. * Department of M edicine, Sungkyunkwan University School of M edicine, Cardiac and Vascular Center, Samsung M edical Center *, Samsung B iomedical R esearch Institute Institute of M olecular and Genetic B iology, Seoul N ational University Division of Cardiology, Department of M edicine, Chungnam N ational University B ackg round : T he purpose of this study was to compare gene expression among newly designed eukaryotic expression vectors, and to characterize the pattern of vascular endothelial growth factor (VEGF ) expression using the most potent plasmids DNA vector. Meth ods : After exposure of a beating rat heart (Sprague-Dawley, 250-300g), 5 different types of plasmid DNA was injected directly into the myocardium. Reporter protein was analyzed by ELISA in the extracted heart. Re s ult s : T he vector harboring cytomegalovirus (CMV) promoter and enhancer induced the strongest expression of reporter gene (chloramphenicol acetyl transferase; CAT ) compared to those of pc3.1, pef 1a, RSV, pactin in the rat heart via direct injection of plasmid DNA into the apex (p <0.001). Using pcn- CAT, gene expression showed a dose- dependent response over a range of 0.3-10. CAT expression could be detected up to 30 days after 10 of pcn- CAT injection with the maximal expression on day 5. In X- gal staining of injected pcn- lacz gene, - galactosidase was found only around the needle track in the apex. The expressed hvegf 12 1 had biologic activity with vascular permeability assay (Miles assay) in guinea pigs. After injection of pcn-hvegf 12 1 into the apex of the rat heart, the expression of VEGF protein was dose- dependent over the range of 25 and : 2000 7 25 : 2000 9 6 :, 50,,, (135-710) E -mail : dkkim @smc.samsung.co.kr - 3 -

Korean Journal of Medicine : Vol. 60, No. 1, 2001 500. VEGF expression was detected up to 14 days with its peak on day 2 after injection of 250 of pcn- hvegf 12 1. When plasmid was injected into the apex of the rat heart, the expression of VEGF in the heart showed concentration gradient from the apex to the base. However, the expression of CAT was detected only in the apex. Conclu s ion : Plasmids vector with hcmv IE promoter/ enhancer will provide clear advantages over other previously developed plasmids and the information regarding the behaviors of VEGF expression may be useful in angiogenic gene therapy of the heart.(korean J Med 60:3-15, 2001) Key W ords : Gene therapy; Plasmids; Endothelial growth factors; Promoter regions(genetics) ( ) (angiogenic gene therapy) (angiogenic factor)., 1-4 )... plasmid (prom oter ),, housekeeping, - (tissue specific). intron 1 enhancer cis- acting element 5, 6 ). intron plasmid,, reporter gene chloramphenicol acetyl transferase (CAT ) hvegf 12 1. 1. Plasmid pcdna3.1- CAT, pcn- CAT, pcn- lacz, pef - CAT, pact- CAT, prsv- CAT Promega. pcn, pef, pact pcdna3.1 backbone pcdna3.1 587 bp CMV IE Invitrogen. Figure 1 7). pcdna3.1 pcn cytomegalovirus immediate early (CMV IE), prsv rous sarcome virus, pef pact housekeeping gene elongation factor 1- alpha beta actin. pcn pcdna3.1 CMV exon 1, intron 1, exon 2 AT G. pef pact exon 1, intron 1, exon 2. 2. 250-300 gram 11-14 Sprague- Dawley rat. Ketamine ( 50 mg/ ml) Xylazine ( 23.32 mg/ ml) 3 : 17 0.5 ml. (Natume, Japan, model PT.2-11622) midline - 4 -

Jin- Ok Jeong, et al : Characteristics of gene transfer and VEGF expression using naked plasmid vectors in the rat heart. DNA purification kit (Qiagen ) plasmid DNA 50 L 29 gage 1 ml needle 2 mm 45. 3-0 black silk. Cephalosporine sodium (Cefamezin, 1.0 g/ vial) 0.1 g/ 1 ml normal saline, cage.. CAT ELISA, VEGF ELISA, X- gal. 3. CAT ELISA ice- cold PBS 1/ 3 2 ml CAT lysis buffer (Boehringer Mannheim ) homogenize 4 o C, 12,000 rpm 10. 1/ 100 10 L Braford (Bio- Rad ) CAT ELISA kit (Boehringer Mannheim ) CAT. 4. LacZ ice- cold PBS 1/ 3 tissue mold O.C.T (Lipshow ) mold - 70 o C. 10 ice- cold 4% paraformaldehyde (ph 7.4, Sigma ) 5. 2 mm MgCl2/ PBS (ph 7.4, Sigma ) X- gal (4 mm potassium ferricyanide, 4 mm potassium ferrocyanide, 2 mm MgCl2, 400 / ml X- Gal) 4 lacz eosin 80% alcohol, 90% alcohol, 100% alcohol, xylene cover glass. (Olymphus ) 40, 200. 5. ACP-hVEGF12 1 VEGF adeno- associated virus IT R (inverted terminal repeat) ACP EcoRI site PCR cloning human VEGF 12 1 cdna ACP- hvegf 12 1. 6. Transient transfection VEGF ELISA 293T 10% fetal bovine serum (FBS)/ DMEM (Gibco BRL ) 6 well plate 70% confluent. T ransfection 3 ACP- hvegf 12 1 DNA/ 200 L serum free media (OPTI- MEM, Gibco BRL ) liposome FuGENE 6 (Roche ) 9 L 10. 6 10% FBS/ DMEM 48 VEGF ELISA kit (R&D ). 7. Miles assay Vascular permeability factor VEGF Miles assay. Male guinea pig (300-450 g) (, ). Evans blue dye PBS 0.5% (w/v), 0.22 filter 1 ml (femoral vein). 30 ACP ACP- hvegf 12 1 transfection 293T 1 ml 100 L (intradermal) evans blue dye. 8. VEGF ELISA CAT ELISA homogenize 4 o C, 12,000 rpm 10-5 -

: 60 1 485 2001. 1/ 100 10 L Braford (Bio- Rad ). 200 L (calibrator 1:1 ) VEGF. 10. InStat program (version 2.02) Kruskal- Wallis test, p 0.05,. 1. 1) CAT 56. pcdna3.1- CAT, pcn- CAT 15, prsv- CAT, pef- CAT 9, pact- CAT 8 plasmid DNA 30. 3 CAT ELISA. CAT pcn- CAT CAT 1856.7 287.1 pg/ mg, pcdna3.1- CAT 256.0 28.1 pg/ mg, prsv- CAT 227.5 30.6 pg/ mg, pef- CAT 328.6 72.4 pg/ mg, pact- CAT 160.6 35.7 pg/ mg CAT (Figure 2). pcn CAT pcdna3.1, prsv, pact (p <0.001), pef (p <0.01). pcdna3.1 prsv, pef, pact CAT. CMV intron 1 pcn- CAT pcdna3.1- CAT 7.3. 2) pcn-cat dose, time-response curve pcn- CAT DNA. 3 CAT ELISA. pcn- CAT 0.3 10 10 30 plateau, (Figure 3A). Fig ure 1. Structure of plasmid vectors. Arrows indicate direction of transcription. pcdna3.1 contains hcmv promoter (Invitrogen Inc.). pcn contains hcmv promoter, exon 1, intron 1 and partial exon 2. prsv contains RSV promoter. pef contains elongation factor 1- promoter, exon 1, intron 1 and partial exon 2. pact contains beta actin promoter, exon 1, intron 1 and partial exon 2. hcmv, human cytomegalovirus; RSV, rous sarcoma virus Fig ure 2. Comparison of chloroampenicol acetyltransferase expression level among different promoters of plasmid DNA in the rat heart. Each 30 pdna was directly injected into the apex with pcdna3.1 (n=15), pcn (n=15), prsv (n=9), pef (n=9) and pact (n=8). CAT assay was done by ELISA with extracted heart at 3 days after plasmid injection. The level of CAT gene expression using pcn was significantly higher than those of other promoters (* p <0.001). Values are mean S.E.M. - 6 -

11 : plasmid VEGF Fig ure 3. A. Dose- response of the injected pcn- CAT expression in the rat heart (3 rats for each group). CAT assay was done by ELISA with extracted heart in 3 days after direct injection of pdna into the rat heart. There was a dose- responsive relation from 0.3 to 10, then plateaued, followed by decrease of gene expression in higher doses. Values are mean S.E.M. B. Time-response of the injected pcn-cat expression in the rat heart (3 rats for each group). CAT assay was done by ELISA with extracted heart after direct injection of 10 of pcn- CAT. CAT expression was detected at 1, 3, 5, 7, 14, 30 days after injection with maximal expression at 5th day. Values are mean S.E.M. F ig ure 4. Histochemical analysis of - galactosidase expression in the rat heart, five days after direct injection of 10 of pcn- lacz DNA. Dark blue staining indicates active expression of - galactosidase. A. Expression of pcn- lacz: - galactosidase could be detected around the needle track in the apex (original magnification 40). B. Expression of pcn- lacz and infiltration of inflammatory cells (original magnification 200). C. Expression of pcn- lacz purified with endotoxin- free column: - galactosidase was expressed and the degree of infiltration of inflammatory cells was similar to the one with plasmids without purification of endotoxin (original magnification Cytoplasmic 200). lacz, pcn- CAT DNA 10. CAT 5 30 (Figure 3B). 3) LacZ pcn- lacz DNA 10, 5 X- gal. - 7 - (needle injection) (Figure 4A). - galactosidase (Figure 4B). E- coli endotoxin contamination, endotoxinfree column DNA. Endotoxin- free column - galactosidase

Korean Journal of Medicine : Vol. 60, No. 1, 2001 (Figure 4C). 2. VEGF 1) ACP-hVEGF12 1 VEGF ACP- hvegf 121 VEGF 293T ACP- hvegf 12 1 FuGENE 6 transient transfection, VEGF ELISA. Negative control (ACP transfection) ACP- hvegf 12 1 transfection VEGF (2.9 0.8 ng/ ml versus 62.7 7.5 ng/ ml p <0.001). (Figure 5). 3) pcn-hvegf12 1 dose, time-response curve 2) hvegf12 1 (Miles permeability assay) ACP- hvegf 121 VEGF guinea pig evans blue dye guinea pig. VEGF, hvegf 12 1 transfection permeability hvegf 12 1 VEGF, ACP- mvegf 120 Fig ure 5. Miles assay of VEGF. Biologic activity of VEGF 12 1 w as demonstrated with vascular permeability assay in guinea pig. Intravenous injection of Evans blue dye via femoral vein followed by intradermal injection of standard proteins or supernatant of ACP - hvegf 12 1 tansfected 293T cells. T here were blue dots around intradermal injection site showed extravasation of evans blue dye due to increased vascular permeability of VEGF. Left lane was recombinant murine VEGF peptide as standard (ST D). Dot size and intentsity of deep blue color were VEGF dose- dependent. Right lanes showed larger deep blue dots around intradermal injection of ACP - hvegf 12 1 and ACP - mvegf 12 0 conditioned media than ACP conditioned media as a negative control. Fig ure 6. A. Dose- response of pcn- hvegf 12 1 expression. Each pdna was directly injected in the rat heart, where n=3 for each group. VEGF ELISA assay was done 2 days after injection. Expression of VEGF was dose- dependent from 25 to 500 of pcn- hvegf 12 1 DNA injection. Values are mean S.E.M. B. Time- response of pcn- hvegf 12 1 expression after injection of 250 pcn-hvegf12 1 in the rat heart, where n=3 for each group. VEGF expression could be detected from 1 days upto 14 days after injection with maximal expression on day 2. Values are mean S.E.M. - 8 -

Jin- Ok Jeong, et al : Characteristics of gene transfer and VEGF expression using naked plasmid vectors in the rat heart ACP- hvegf 121 hvegf 121 c DNA pcn pcn- hvegf 12 1. 2 VEGF ELISA. VEGF DNA (Figure 6A). pcn- hvegf 12 1 250. VEGF 2 14 VEGF (Figure 6B). 4) pcn-hvegf12 1 VEGF VEGF 10 pg/ mg pcn CAT 1,800 pg/ mg. VEGF 1, VEGF 12 1 heparin- binding domain, VEGF Fig ure 7. Spatial distribution of protein produced by gene injection. A. Spatial distribution of CAT protein after a single injection of pcn- CAT 10 in the apex of the rat heart. T hree hearts at day 3 after injection were analyzed. CAT protein was detected only in the apex. Values are mean S.E.M. B. Spatial distribution of VEGF protein after a single injection of pcn- hvegf 12 1 250 in the apex of the rat heart. Six hearts at second day after injection were analyzed. Concentration gradient of VEGF protein was noted from the apex to the base. Values are mean S.E.M.. plasmid DNA VEGF CAT, pcn- hvegf 121 250 (n=6) pcn- CAT 10 (n=3). VEGF 2, CAT 3 4 VEGF, CAT. CAT 6264.2 1226.3 pg/ mg, 0.9 0.2 pg/ mg, 1.0 0.3 pg/ mg, 0.7 0.1 pg/ mg plasmid DNA (Figure 7A). VEGF 26.3 5.2 pg/mg, 11.7 1.3 pg/ mg, 12.2 1.5 pg/ mg, 6.8 0.8 pg/mg VEGF plasmid DNA VEGF (Figure 7B). 1.. retrovirus, adenovirus, adenoassociated virus, retrovirus,. in vivo 1% 8-10 ), (granulation tissue) 14% 11). Adenovirus, adenovirus plasmid DNA 6-7 12, 13 ). adenovirus 100% lacz 14), adenovirus rabbit, plasmid DNA 50 15). adenovirus - 9 -

: 60 1 485 2001 adenovirus immunogenicity, 2 13). ornithine transcarbamylase adenovirus adenovirus. adenovirus negative control, adenovirus. adenovirus. Adeno- associated virus,,,,. 2. naked DNA naked DNA. Naked DNA,,,,. naked DNA., naked DNA (striated muscle). Naked DNA 8 16 ), 50 17, 18 )., naked DNA 19 )., (hypoxia) upregulation 20 )., retovirus VEGF (angioma- like lesion) 2 1),. w all tension naked DNA. Naked DNA naked DNA. naked DNA 1-3 ).. plasmid, DNA,,. 3. Naked DNA naked DNA in vivo, reporter gene CAT pcn > > pef > pcdna3.1 > prsv > pact pcn CAT. pcdna3.1 Invitrogen - 10 -

11 : plasmid VEGF,, Isner. pcn pcdna3.1 7.3.. Buttrick 22 ) adult female Wistar rats 100 naked DNA luciferase reporter. RSV, - myosin heavy chain ( MHC) 1- antitrypsin RSV >> MHC > 1- antitrypsin, RSV MHC 20. RSV. pcn, pcdna3.1, prsv, pef, pact. CMV IE Overell 23 ) primary B lympocytes CMV- IE Moloney murine leukemia virus long terminal repeat (MoMLV LT R) SV40 early region reporter gene CAT, Hippenmeyer 24 ) quail cell SV40 early, mouse metallothionein I, CMV- IE CMV. pcdna3.1 prsv CAT. CMV RSV. EF - 1 human EF - 1. intron 1 Sp1, Ap1. pef intron 1 Nagata pef321 5, 6). pef CMV. Beta actin housekeeping gene. Beta actin,. pcn CMV IE exon 1, intron 1, exon 2. CMV EF 1- AT G site 5' - untranslated region. Simari 25 ) human CMV IE CMV 5' - untranslated sequence exon 1 intron 1 5.7, RSV 10.3 (enahncer). pcn pcdna3.1 7.3. CMV- IE / (, exon 1, intron 1 ). 4. naked DNA CAT dose, time-response pcn- CAT 0.3-10 10-30 plateau,. Li 26) CD1 RSV rat - MHC naked plasmid DNA luciferase activity, RSVluc 0.3 3 plateau. CAT. 100-11 -

Korean Journal of Medicine : Vol. 60, No. 1, 2001. Heller 27 ) electroporation luciferase - galactosidase naked DNA 25, 50 500, Harsdorf 28) mouse sarcoma virus- CAT CAT 10 200 300, reporter gene. pcn- hvegf 12 1 VEGF 500,. pcn- CAT 10 5, 30. Li 26) CD1 RSV rat - MHC naked plasmid DNA luciferase activity luciferase 1, Lin 18) in vivo 6-11 Sprague- Dawley RSV 100 - galactosidase plasmid DNA 4. Buttrick 22 ) prsv- CAT prsv- Luc naked DNA 100 Wistar rat CAT luciferase, 1 7 100%, 17 23 60%, 38 60 30%, 7-10. pcn- CAT - naked DNA. 5.. Li 26 ) naked DNA 1-2 mm, luciferase, (septum), c- myc myc- specific monoclonal antibody c- myc. Buttrick 22 ) Wister rat prsvluc 5 1-2 mm. Lin 18 ) prsv - galactosidase Sprague- Dawley rat - galactosidase. - galactosidase, naked DNA naked DNA., Quiagen DNA purification E. coli endotoxin, endotoxin- free column DNA endotoxin., E- coli - galactosidase, lacz. - galactosidase. VEGF 1), VEGF naked DNA. 6. CAT VEGF pcn- hvegf 121 naked plasmid VEGF 12.4 1.2 pg/ mg pcn- CAT CAT 1856.7 287.1 pg/ mg, time- response VEGF - 12 -

Jin- Ok Jeong, et al : Characteristics of gene transfer and VEGF expression using naked plasmid vectors in the rat heart 2 CAT 5. CAT,., VEGF 1, VEGF 12 1 heparin- binding domain, VEGF. pcn- lacz LacZ, pcn- CAT CAT plasmid DNA VEGF VEGF. hvegf 121. pcn mrna level pcn- CAT pcn-hvegf 121 VEGF time- response, RT - PCR mrna naked DNA. CAT 10, 5 30., hvegf 12 1 cdna VEGF vascular permeability., pcn- hvegf 12 1 VEGF plasmid 500, 2, 14., VEGF plasmid DNA., CAT plasmid DNA. : naked DNA CMV intron 1 pcn. VEGF plasmid,, 14 VEGF kinetics VEGF. hvegf 12 1 cdna. : intron plasmid,, reporter gene chloramphenicol acetyl transferase (CAT ) hvegf 12 1. : 250-300 gram 11-14 Sprague- Dawley rat plasmid DNA. :, hcmv IE intron 1 pcn., pcn- CAT reporter gene 1999 (HMP- 99-B-02-0001) (C98-002). R E F E R E N C E S 1) Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Constitutive exp ression of phve GF1 65 af ter intramuscular gene transf er p romotes collateral vessel developm ent in patients with critical limb ischemia. Circulation 97:1114-1123, 1998 2) Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: - 13 -

: 60 1 485 2001 initial clinical results with direct myocardial inj ection of phvegf165 as sole therapy for myocardial ischemia. Circulation 98:2800-2804, 1998 3) Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M, Isne JM. Gene therapy with vascular endothelial growth factor f or inop erable coronary artery disease. A nn Thorac Surg 68:830-837, 1999 4) Rosengart T K, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW, Hachamovitch R, Szulc M, Kligfield PD, Okin PM, Hahn RT, Devereux RB, Post MR, Hackett NR, Foster T, Grasso T M, Lesser ML, Isom OW, Crystal RG. A ngiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector exp ressing VE GF12 1 cdna to individuals with clinically significant severe coronary artery disease. Circulation 100:468-474, 1999 5) Mizushima S, Nagata S. pef - B OS, a p owerful mammalian exp ression vector. N ucleic A cids R es 18:5322, 1990 6) Wakabayashi- Ito N, Nagata S. Characterization of the regulatory elements in the p romoter of the human elongation factor-1 alpha gene. J B iol Chem 269:29831-29837, 1994 7) Lee YJ, Park EJ, Yu SS, Kim DK, Kim S. Imp roved exp ression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: imp lication for gene therapy of ischemic disease. B iochem B iophys R es Commun 272:230-235, 2000 8) Ferry N, Duplessis O, Houssin D, Danos O, Heard JM. R etroviral-mediated gene transfer into hepatocytes in vivo. P roc N atl A cad Sci USA 88:8377-8381, 1991 9) Gojo S, Kitamura S, Germeraad WT, Yoshida Y, Niwaya K, Kawachi K. Ex vivo gene transf er into myocardium using rep lication- defective retrovirus. Cell T ransp lant 5:S81-84, 1996 10) Huh JE, Kim DK, Byun JH, Park SJ, Jeon ES, Choe YH, Jung EA, Gwon HC, Park SW, Kim JS, Lee SH, Hong KP, Park JE, Cosset FL, Sei JD, Lee WR. Gene transf er into cultured cardiac myocytes m ediated by retrovirus. K orean Circ J 29:182-191, 1999 11) Byun J, Huh JE, Park SJ, Jang JE, Suh YL, Lee JS, Gwon HC, Lee WR, Cosset FL, Kim DK. M yocardioal inj ury- induced fibroblast p rolif eration facilitates retroviral- mediated gene transf er to the rat heart in vivo. J Gene M ed 2:1-9, 2000 12) Kass-Eisler A, Falck-Pedersen E, Alvira M, Rivera J, Buttrick PM, Wittenberg BA, Cipriani L, Leinwand LA. Quantitative determ ination of adenovirusmediated gene delivery to rat cardiac myocytes in vitro and in vivo. P roc N atl A cad Sci USA 90: 11498-11502, 1993 13) Guzman RJ, Lemarchand P, Crystal RG, Epstein SE, Finkel T. Efficient gene transfer into myocardium by direct inj ection of adenovirus vectors. Circ R es 173:1202-1207, 1993 14) Donahue JK, Kikkawa K, Johns DC, Marban E, Lawrence JH. Ultrarap id, highly eff icient viral gene transf er to the heart. P roc N atl A cad Sci USA 94:4664-4668, 1997 15) Barr E, Carroll J, Kalynych AM, Tripathy SK, Kozarsky K, Wilson JM, Leiden JM. Efficient cathetermediated gene transf er into the heart using rep lication- def ective adenovirus. Gene Ther 1:51-58, 1994 16) Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transf er into mouse muscle in vivo. Science 247:1465-1468, 1990 17) Kitsis RN, Buttrick PM, McNally EM, Kaplan ML, Leinwand LA. H ormonal modulation of a gene inj ected into rat heart in vivo. P roc N atl A cad Sci USA 88:4138-4142, 1991 18) Lin H, Parmacek MS, Morle G, Bolling S, Leiden JM. Exp ression of recombinant genes in myocardium in vivo af ter direct inj ection of DNA. Circulation 82:2217-2221, 1990 19) Levy AP, Levy NS, Loscalzo J, Calderone A, T akahashi N, Yeo KT, Koren G, Colucci WS, Goldberg MA. R egulation of vascular endothelial growth factor in cardiac myocytes. Circ R es 76: 758-766, 1995 20) Banai S, Shweiki D, Pinson A, Chandra M, Lazarovici G, Keshet E. Up regulation of vascular endothelial growth factor exp ression induced by myocardial ischemia: imp lications f or coronary angiogenesis. Cardiovasc R es 28:1176-1179, 1994 21) Springer ML, Chen AS, Kraft PE, Bednarski M, Blau HM. VE GF gene delivery to muscle: potential role f or vasculogenesis in adults. M ol Cell 2:549-558, 1998 22) Buttrick PM, Kass A, Kitsis RN, Kaplan ML, Leinwand LA. B ehavior of genes directly inj ected into the rat heart in vivo. Circ R es 70:193-198, 1992 23) Overell RW, Weisser KE, Hess BW, Ziegler SF, Pleiman CM, Maliszewski C, Grabstein KH. Eff icient gene transf er and exp ression in p rimary B lymphocytes. J Imm unol M ethods 141:53-62, 1991 24) Hippenmeyer PJ, Krivi GG. Gene exp ression f rom heterologous p romoters in a rep lication- def ective avian retrovirus vector in quail cells. P oult Sci 70:982-992, 1991 25) Simari RD, Yang ZY, Ling X, Stephan D, Perkins - 14 -

11 : plasmid VEGF ND, Nabel GJ, Nabel EG. R equirem ents f or enhanced transgene exp ression by untranslated sequences from the human cytom egalovirus immediate- early gene. M ol M ed 4:700-706, 1998 26) Li K, Welikson RE, Vikstrom KL, Leinwand LA. Direct gene transf er into the mouse heart. J M ol Cell Cardiol 29:1499-1504, 1997 27) Heller R, Jaroszeski M, Atkin A, Moradpour D, Gilbert R, Wands J, Nicolau C. In vivo gene electroinj ection and exp ression in rat liver. FEB S L ett 389:225-228, 1996 28) von Harsdorf R, Schott RJ, Shen YT, Vatner SF, Mahdavi V, Nadal- Ginard B. Gene inj ection into canine myocardium as a usef ul model f or studying gene exp ression in the heart of large mammals. Circ R es 72:688-695, 1993-15 -